Since the onset of the coronavirus pandemic, Jubilant HollisterStier has been busy churning out COVID-19 treatments and more recently vaccines. Now it’s turning those revenues from the increased business into an investment in the future. The Spokane, Washington-based CDMO revealed a $ 92 million expansion plan this week that includes a high-speed injectable fill line with… Read More »
Shortly after rolling out interim data on its COVID-19 antibody hopeful, Eli Lilly last week sent the therapy ahead to the FDA for a potential emergency nod. If the antibody crosses the finish line, Lilly can expect a huge surge in demand—and it’s bringing in a manufacturing partner to help out. Lilly has signed on… Read More »
Outside of vaccines, GlaxoSmithKline isn’t a major producer of biologics compared with some of its Big Pharma peers. But it has just signed a big deal to scale up manufacturing in the field. The British pharma tapped South Korean CDMO Samsung Biologics in a deal worth more than $ 231 million to help it make biologic… Read More »
(Reuters) – Privately held drug developer Enzyvant said on Thursday the U.S. Food and Drug Administration declined to approve its regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about its manufacturing. The company was hoping to win its first approval for the therapy, RVT-802, aimed at treating congenital athymia, a disorder affecting… Read More »
Horizon Therapeutics, once known for its primary care drugs, is looking to pivot further to rare diseases with the FDA scrutinizing its late-stage inflammatory eye disease candidate. In the meantime, Horizon is, well, looking to the horizon with a new manufacturing and R&D facility that could help boost its growing pipeline. Horizon recently opened a… Read More »